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Poxviruses that are attenuated for growth in human cells provide a safe means of HIV antigen expression and are capable
of eliciting HIV-specific immune responses, including CD81 cytotoxic T-lymphocyte (CTL) responses. HIV-1 antigen expres-
sion in human cells by attenuated poxvirus vectors may be limited by interferon-mediated host defense mechanisms. To
enhance HIV antigen expression in human cells, the vaccinia virus E3L and K3L genes were inserted into a canarypox vector
that expresses HIV-1 Gag, Env, and a Nef/Pol polyepitope string. E3L and K3L markedly reduced the activation of the
double-stranded RNA-dependent protein kinase, PKR, and led to a significant reduction in apoptosis in HeLa cells. Production
and release of HIV-1 antigen in the form of pseudovirions was enhanced in both duration and magnitude by this vector
modification. The addition of immunomodulatory genes to attenuated poxviruses represents a novel strategy for enhancing
antigen production by live vector HIV vaccine candidates. © 2001 Elsevier Science
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Live virus vectors expressing human immunodefi-
ciency virus (HIV) antigens are essential components of
many HIV vaccine regimens currently under evaluation in
human trials. One reason that live vector HIV vaccine
candidates hold a prominent position in current trials is
because they have proven much more effective at gen-
erating HIV-specific cytotoxic T-lymphocyte (CTL) re-
sponses than have subunit protein approaches (Letvin,
1998). Recent studies using the SIV/macaque model of
AIDS pathogenesis have established the importance of
CTL in controlling viremia (Schmitz et al., 1999) and have
indicated that induction of a CD81 CTL response by a
vaccination regimen can control viral replication and
protect animals from disease (Barouch et al., 2000; Letvin
et al., 1999). Recombinant poxviruses have been estab-
lished as some of the leading candidate products for
inducing HIV-specific CTL responses in humans.
Recombinant vaccinia viruses achieve high levels of
antigen expression and replicate well within human
cells. However, concerns with the potential toxicity of
wild-type vaccinia viruses in humans have led to the
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272advancement of highly attenuated vaccinia strains that
are unable to replicate in human cells (Moss et al., 1996).
Modified vaccinia Ankara (MVA) is an attenuated vac-
cinia strain that was derived by greater than 500 serial
passages of the Ankara vaccinia strain on chicken em-
bryo fibroblasts. MVA harbors multiple genomic dele-
tions that alter the host range of the virus, rendering it
replication-deficient in most but not all mammalian cell
lines (Carroll and Moss, 1997; Meyer et al., 1991). NYVAC
is an attenuated vaccinia strain that was created by
engineering deletions of virulence genes from the
Copenhagen strain of vaccinia virus (Tartaglia et al.,
1992b). Canarypox viruses are members of the avipoxvi-
rus genus that are naturally restricted to replication in
avian cells (Taylor et al., 1995).
Recombinant canarypox vaccine vectors have been
evaluated in phase I and phase II clinical trials in hu-
mans, where they have generated significant immune
responses. ALVAC is the designation given to a canary-
pox virus vector system derived from a plaque-purified
isolate from the attenuated canarypox strain Kanapox
(Tartaglia et al., 1992a). When combined with a subunit
envelope glycoprotein boost, ALVAC-HIV vaccines have
been shown to successfully prime neutralizing antibody
responses directed against HIV-1 laboratory strains and
against a limited number of primary isolate viruses (Mul-
ligan and Weber, 1999; Verrier et al., 2000). CD81 cyto-
toxic T-lymphocyte responses have been elicited in 56–
64% of volunteers receiving ALVAC-HIV vectors, and CTL
responses in some volunteers have been detected up to
2 years following vaccination (Evans et al., 1999; Fleury
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finding from recent trials was the finding that ALVAC-
based vaccine regimens elicit CTL responses that can
kill target cells infected with HIV from multiple clades
(Ferrari et al., 1997). Despite these encouraging results,
improvements to ALVAC-HIV vectors are warranted to
enhance HIV-specific responses. CTL responses in vac-
cines are often detectable at only one or a few time
points during a trial, suggesting that the magnitude or
durability of the response in most vaccinees is limited
(Tartaglia et al., 1998b). Although the magnitude of the
CTL response required for vaccine efficacy is not known,
it would be desirable to enhance the current ALVAC-HIV
vectors to elicit cellular immune responses that are more
sustained, more frequently detected, and present in a
higher proportion of vaccine recipients. One potential
method to achieve this goal is by engineering vectors
that generate more HIV-1 antigen in human cells and
sustain their production for a longer period of time.
We recently characterized HIV-1 antigen expression by
ALVAC vector vCP205 in avian, simian, and human cell
lines (Fang et al., 1999). This vector, which encodes HIV-1
Gag and protease proteins and a membrane-anchored
gp120 molecule, was found to be capable of eliciting the
formation of Gag-Env pseudovirions in a wide variety of
cell lines. However, the amount of Gag antigen ex-
pressed by vCP205 was strictly cell-type dependent, with
some cell lines (BSC-40, Vero, C2C12) capable of pro-
ducing large amounts of released pseudovirion particles,
while others generated very low amounts of released
particles. Although there were some differences in the
efficiency of particle release between individual cell
lines, most of the restriction in pseudovirion production
in low-producing cell lines was due to poor intracellular
antigen expression (Fang et al., 1999). Especially striking
was the poor production of pseudovirions by vCP205 in
human cell lines. Given the safety profile and proven but
limited success of ALVAC-HIV vectors as immunogens in
humans, it is logical to pursue methods of enhancing the
expression of HIV antigens by these vectors in human
cells. One method of enhancing antigen expression is
through inhibition of IFN-stimulated host defense mech-
anisms that limit viral antigen expression in human cells.
Most viral infections generate double-stranded RNA
(dsRNA) as a replication intermediate of the viral life-
cycle. PKR is a well-characterized IFN-induced gene
product that binds to dsRNA and plays a key role in the
host response to viral infection. PKR binds to dsRNA
through binding motifs in its amino terminus; this binding
promotes PKR dimerization and autophosphorylation
(Wu and Kaufman, 1997). Phosphorylated, dimeric PKR
represents the active form of the enzyme that can rec-
ognize and phosphorylate the eukaryotic translation ini-
tiation factor eIF-2 on its a-subunit (Wek, 1994). Phos-
phorylated eIF-2 complexed with GDP then forms a sta-
ble complex with eIF-2B, sequestering this translationfactor from participating in subsequent translation initia-
tion events. In this manner, PKR activation by viral infec-
tions restricts viral as well as cellular protein synthesis.
To overcome this IFN-induced antiviral defense mecha-
nism, numerous viruses have evolved methods to inhibit
PKR function (reviewed in Gale and Katze, 1998). The
interferon resistance of vaccinia virus has been mapped
to two ORFs, E3L and K3L (Beattie et al., 1995a,b). The
E3L gene product is a dsRNA-binding protein that se-
questers the dsRNA normally produced during viral rep-
lication, preventing activation of PKR (Davies et al., 1993).
K3L is a homolog of EIF-2a and downregulates PKR
activity by acting as a competitor substrate for PKR-
mediated phosphorylation (Davies et al., 1993, 1992; Ja-
gus and Gray, 1994). PKR activation following viral infec-
tion is also a potent stimulus for apoptosis, and E3L
deletion from vaccinia virus results in greatly enhanced
apoptosis in infected HeLa cells (Lee and Esteban,
1994).
We sought to test the hypothesis that inhibition of PKR
by coexpression of the vaccinia virus E3L and K3L gene
products would remove the relative restriction to antigen
production in human cells observed with recombinant
canarypox viruses, thus stimulating enhanced pseudo-
virion production and the potential for greater immuno-
genicity. The data supporting this approach included the
following: (1) deletion of K3L and/or E3L from vaccinia
reduced viral gene expression in human cells (Tartaglia
et al., 1998a); (2) deletion of E3L was found to reduce
vaccinia virus propagation in human cells (Beattie et al.,
1996); (3) deletion of E3L and K3L was not found to
debilitate vaccinia virus propagation on avian-derived
cells (Beattie et al., 1996); and (4) canarypox virus does
not encode gene products with homologous functions to
E3L and K3L (Tartaglia et al., 1998a and unpublished
observations). In this study, we demonstrate that the
addition of the vaccinia virus E3L and K3L genes to the
genome of a recombinant ALVAC-HIV vaccine candidate
vector inhibited activation of PKR following viral infection.
The modified vector, vCP1452, demonstrated markedly
reduced apoptosis in HeLa cells. The magnitude and
duration of HIV-1 pseudovirion production following in-
fection with vCP1452 was greater than that elicited by
vCP205 in each of four human cell lines tested. These
results may have bearing on vector choices for future
poxvirus-based HIV vaccine trials. The addition of immu-
nomodulatory genes to a naturally attenuated poxvirus
vaccine represents a promising approach to HIV vaccine
design.
RESULTS
Generation of recombinant ALVAC vCP1452
The ALVAC-HIV vector that has been best character-
ized in studies in vitro and in human trials is vCP205. This
recombinant vector includes an HIVLAIgag-pro expres-
ccinia
s. Arro
274 FANG ET AL.sion cassette and an envelope expression cassette that
creates a fusion of the HIV-1MN gp120 protein to the 18
amino acid transmembrane region from gp41 of HIV-1LAI.
To enhance the breadth of the CTL response elicited by
this vector, a polyepitope string encoding Pol and Nef
MHC class I restricted CTL epitopes was inserted into
vCP205 to create vector vCP1433. The design and con-
struction of both of these vectors has been previously
described (Tartaglia et al., 1998a,b). To achieve en-
hanced antigen expression from previous ALVAC-based
HIV vaccine vectors, expression cassettes for the vac-
cinia virus E3L and K3L genes were created and inserted
into the existing ALVAC-HIV vector vCP1433 to create
recombinant virus vCP1452. A schematic diagram of the
genome of vCP1452 is illustrated in Fig. 1. This recom-
binant virus contains three engineered HIV gene expres-
sion cassettes (gag-pro, gp120/TM, and a Nef/Pol poly-
epitope string) and expression cassettes for two vaccinia
virus genes (E3L, K3L) (Fig. 1). The gag/pro/env expres-
sion cassette was inserted in the C3 locus, the nef/pol
string was inserted in the C5 locus, and the E3L, K3L
expression cassette was inserted in the C6 locus. Be-
cause the C3 and C5 loci are located within the inverted
terminal repeat region, the Env/Gag and Nef/Pol cas-
settes are present in two copies in ALVAC genome. This
vaccine vector differs from the best studied ALVAC vec-
tor, vCP205, only in the addition of the Nef/Pol poly-
epitope string and the E3L and K3L expression cas-
settes. The correct insertion of E3L and K3L gene ex-
pression cassettes in vCP1452 was verified by Southern
blotting (data not shown).
Expression of E3L, K3L gene products
To demonstrate production of the E3L and K3L gene
products by vCP1452, CEFs were infected with parental
ALVAC (lacking any foreign insert) or with vCP1452. Ex-
FIG. 1. Genome map of vCP1452. Insertion of HIV-1 genes and of va
the ALVAC genome. Solid boxes represent poxvirus promoter elementpression of the E3L gene product was detected in CEFs
infected with vCP1452 but not in cells infected withparental ALVAC or in uninfected cells by metabolic label-
ing and immunoprecipitation (Fig. 2A). The E3L gene
product was present as both a 25-Kd and a 20-Kd spe-
cies, as described previously in vaccinia virus-infected
cells (Beattie et al., 1995b). Expression of the 10-Kd K3L
gene product was clearly demonstrated in cells infected
by vCP1452 and not in control cells (Fig. 2B). These
results demonstrate that vCP1452 expresses the vac-
cinia virus E3L and K3L gene products as designed.
Differential activation of PKR phosphorylation by
vCP1452 and vCP205
The vaccinia virus E3L and K3L genes were included
in the design of vCP1452 to enhance HIV antigen expres-
sion through suppression of the IFN-inducible, double-
stranded RNA-dependent protein kinase (PKR). Activa-
tion of PKR is accompanied by autophosphorylation on
serine and threonine residues (Taylor et al., 1996). To
directly assess the effects of canarypox-encoded E3L
and K3L on activation of PKR, we compared the induction
of the active, phosphorylated form of PKR in HeLa cells
infected with vCP205 or vCP1452. vCP205 was included
as the comparator virus because it contains the identical
Gag-pro and gp120 expression cassettes and because
this vector has been evaluated extensively in human
trials (Mulligan and Weber, 1999) and in cell-based as-
says of antigen production (Fang et al., 1999). HeLa cells
were infected with either poxvirus vector at a multiplicity
of infection (m.o.i.) of 10 PFU/cell and were preincubated
where indicated with b-IFN to enhance PKR expression
prior to viral infection. The addition of b-IFN to HeLa cells
resulted in a small increase in active PKR due to en-
hanced expression of PKR (Fig. 3A, lanes 1 and 2).
vCP205 infection of HeLa cells resulted in a significant
increase in phosphorylated PKR either following b-IFN
treatment (Fig. 3A, lane 5) or in the absence of b-IFN
E3L, K3L genes are displayed on a schematic XhoI restriction map of
ws indicate transcriptional orientation.treatment (lane 8). Activation of PKR was detected in
cells infected by vCP1452 only following pretreatment
DS–polyacrylamide gel and visualized by fluorography. M 5 molecular mass
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levels of PKR were increased by b-IFN treatment, but did
not differ substantially following infection with vCP205 or
vCP1452 (Fig. 3A, Western blot shown below autoradio-
gram). The prominence of the band seen in lane 5 of the
immunoblot may be due partially to the presence of
phosphorylated and nonphosphorylated PKR, as the sep-
aration on this blot did not fully resolve the bands but
resulted in a wider band. In the b-IFN-pretreated cells,
the amount of activated PKR induced following vCP1452
infection was substantially less than that induced by
vCP205 (Fig. 3A, compare lanes 4 and 5). Densitometric
analysis of the PKR bands in Fig. 3A revealed that the
activated form of PKR was induced fourfold by vCP1452
(lane 4) as compared to b-IFN alone (lane 2), while
vCP205 caused a ninefold induction (lane 5). This differ-
ence was even more dramatic when b-IFN pretreatment
was not performed. In this case, vCP1452 induced a
2.5-fold increase in activated PKR (lane 7 vs lane 6),
while vCP205 induced a 36-fold activation (lane 8). These
results indicate that the activation of PKR by vCP1452 is
reduced as compared to that of vCP205.
We next compared the activation of PKR by vCP205
and vCP1452 at three different time points postinfection
in cells that had not been pretreated with IFN. At 2 h
postinfection, a faint band representing phosphorylated
PKR was apparent by Western blotting in cells infected
with vCP205 but not vCP1452 (Fig. 3B). The differential
activation of PKR by vCP205 was more apparent by 4 h
postinfection and persisted at 8 h postinfection. At none
of the times tested was the activated form of PKR ob-
served in lysates from vCP1452-infected HeLa cells that
had not been pretreated with IFN. We conclude that the
FIG. 2. Expression of E3L, K3L gene products by vCP1452. (A) Chick
or vCP1452 at an m.o.i. of 10 PFU/cell in methionine- and cysteine-free
cells were lysed 18 h postinfection and the lysates immunoprecipit
fractionated on a 15% SDS–polyacrylamide gel and visualized by fluoro
left of the gel. (B) CEF cells were mock infected or infected with ALVAC
supplemented with [35S]methionine and [35S]cysteine. The cells were l
against K3L (Beattie et al., 1995). Samples were fractionated on a 15% S
marker; mass in kilodaltons is indicated at the left of the gel.en embryo fibroblast (CEF) cells were mock infected or infected with ALVAC
media supplemented with 200 mCi/ml [35S]methionine and [35S]cysteine. The
ated with rabbit antisera against E3L (Watson et al., 1991). Samples were
graphy. M 5 molecular mass marker; mass in kilodaltons is indicated at the
or vCP1452 at an m.o.i. of 10 PFU/cell in methionine- and cysteine-free media
ysed 18 h postinfection and lysates immunoprecipitated with rabbit antiserainduction of PKR activation by vCP205 is apparent at
multiple time points postinfection, and the suppressionFIG. 3. Activation of PKR following infection with vCP205 or vCP1452.
(A) Detection of [32P]PKR. HeLa cells were infected with vCP205,
vCP1452, or mock infected as indicated at the top of the gel. Pretreat-
ment of cells with 50 units/ml b-IFN was performed in some experi-
ments as indicated (1, with; 2, without). Four hours following infection,
cells were labeled with [32P]orthophosphate for 1 h, followed by cell
lysis, immunoprecipitation with rabbit polyclonal anti-PKR antibody, and
analysis via SDS–PAGE. The cell lysates were also analyzed by West-
ern blotting with a murine anti-PKR antibody, as shown immediately
below the autoradiogram. (B) Time course of PKR activation as indi-
cated by immunoblotting. HeLa cells were infected with vCP205,
vCP1452, or mock-infected. Cells were harvested at the time points
indicated above the blot. Cell lysates were immunoprecipitated with
rabbit polyclonal antibody directed against PKR and detected with a
murine monoclonal anti-PKR antibody. Phosphorylated (activated) PKR
is indicated by the appearance of a slower migrating band in the
vCP205 lanes.
276 FANG ET AL.of PKR activation by E3L and K3L results in no detectable
PKR activation at up to 8 h postinfection.
Reduced apoptosis in HeLa cells infected with
vCP1452 as compared with vCP205
The activation of PKR by viral infection is a potent
stimulus for apoptosis (Lee and Esteban, 1994). Apopto-
sis of cells infected with live vaccine vectors such as
recombinant canarypox may limit the duration of antigen
expression and the total amount of antigen produced. To
determine whether the expression of the vaccinia virus
E3L and K3L gene products inhibited apoptosis, we com-
pared the induction of apoptosis in HeLa cells following
infection with vCP205 or vCP1452. We first performed
electrophoretic analysis of chromosomal DNA from cells
infected with the two vectors. vCP205 induced fragmen-
tation of chromosomal DNA into nucleosomal-size frag-
ments (DNA ladder) characteristic of apoptosis (Fig. 4A).
This fragmentation was most apparent at 8 h postinfec-
tion and had progressed to produce a smear of chromo-
FIG. 4. Induction of apoptosis by recombinant canarypox virus. (A)
HeLa cell monolayers were infected with vCP205 or vCP1452 at an
m.o.i. of 10 PFU/cell. Cells were harvested at the time points indicated
above the gel and cellular DNA isolated for analysis by gel electro-
phoresis. M 5 lambda DNA marker, digested with EcoRI and HindIII.
(B) Detection of apoptosis by ELISA. HeLa cells were infected with
vCP205, vCP1452, mock-infected, subjected to UV irradiation, or sub-
jected to treatment with two of the buffers from the Cell Death Detec-
tion ELISA Kit (Roche). The positive control lane represents DNA–
histone complexes included with the kit. Mono- and oligonucleosomes
present in the cytoplasmic fraction of cells were detected using a
sandwich ELISA technique according to the manufacturer’s instruc-
tions. Results shown represent the mean 6 standard deviation of
triplicate assays.somal DNA by 12 h (Fig. 4A). In contrast, no fragmenta-
tion of chromosomal DNA was apparent in cells infectedwith vCP1452 at either the 8 or 12 h time points postin-
fection (Fig. 4A, vCP1452 lanes). To confirm the results of
DNA fragmentation analysis, an ELISA measuring the
cytosolic appearance of mono- and oligonucleosomes
as a measure of apoptosis was next employed. Infection
of HeLa cells with vCP205 resulted in significantly higher
degrees of apoptosis than vCP1452. Figure 4B illustrates
the results of this assay performed on lysates harvested
24 h postinfection. Apoptosis due to infection with
vCP1452 was higher than that of mock-infected cells, but
remained significantly below that of vCP205 (Fig. 4B).
These results support the ability of E3L and K3L present
in vCP1452 to inhibit poxvirus-induced apoptosis through
downmodulation of PKR activation.
HIV antigen production and release is enhanced by
expression of E3L, K3L
Virus-specific antigen expression is inhibited by the
actions of activated PKR. We therefore asked whether
PKR inhibition mediated by E3L and K3L would enhance
HIV gene expression by recombinant ALVAC vectors. We
have previously demonstrated that p24 antigen release
by vCP205 in the form of HIV-1 pseudovirions correlates
well with intracellular antigen production by this vector in
mammalian cells (Fang et al., 1999). To determine
whether the inclusion of the vaccinia E3L and K3L genes
enhanced HIV-specific antigen expression, we mea-
sured p24 antigen release in the supernatant of avian,
simian, and human cell lines following infection with
vCP205 or vCP1452. Data shown are representative of at
least three experiments comparing the vectors in each
cell line. Both vectors produced only low amounts of p24
antigen release from CEFs (Fig. 5A). The low production
of HIV Gag antigen from CEFs was reported previously
and appears to be due not to defects in antigen produc-
tion but to defective particle production and release
(Fang et al., 1999). In contrast, both vectors produced
significant amounts of pseudovirions from the African
green monkey kidney cell line BSC-40 (Fig. 5B). However,
vCP1452 infection resulted in an approximately threefold
enhancement of particle release in this cell line. Next, we
compared HIV-1 pseudovirion release from four human
cell lines. HeLa cells infected with vCP205 produced low
amounts of pseudovirions and did not demonstrate an-
tigen release after the first 24 h (Fig. 5C, open squares).
In contrast, p24 release from HeLa cells infected with
vCP1452 continued for a longer time period and
achieved significantly higher levels (Fig. 5C, filled cir-
cles). At the end of 72 h, total p24 release from HeLa
cells reached 30 ng/million infected cells, a level consis-
tent with the subset of high-particle producing mamma-
lian cell lines in our previous study of vCP205 (Fang et
al., 1999). A similar pattern of enhanced particle release
by vCP1452 was seen in three additional human cell
lines: Hep-2, a human epidermoid carcinoma cell line
MRC-
es.
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5E); and TE671, a human rhabdomyosarcoma cell line
(Fig. 5F). vCP1452 therefore demonstrated superior HIV-1
pseudovirion release from each of the human cell lines
tested. TE671, derived from human muscle, generated
the highest levels of particle release from human cells in
repeated experiments (Fig. 5F and data not shown).
vCP1452 elicits HIV-1 Gag-Env pseudovirion
formation from human cells
To confirm that Gag antigen was released from human
cells infected with vCP1452 in the form of HIV-1
pseudovirions, supernatants from ten 100-mm2 plates of
three cell types were harvested, pelleted through a 20%
sucrose cushion, and subjected to analysis by equilib-
rium density gradient centrifugation. CEFs, despite re-
leasing low total amounts of antigen, generated particles
of a peak equilibrium density of 1.16–1.17 g/ml (Fig. 6A).
Higher amounts of pseudovirions of the same density
were detected from infected BSC-40 cells (Fig. 6B).
Pseudovirion release from TE 671 cells also peaked at a
similar particle density of 1.17–1.18 g/ml (Fig. 6C). These
data demonstrate that vCP1452 elicits the production
and release of particulate Gag antigen of a density iden-
FIG. 5. p24 antigen release from CEFs and human cell lines. Cells we
of 10 PFU/cell, and cellular supernatants harvested at the indicated time
by p24 capture ELISA and reported as nanograms of p24 released pe
p24 release from HeLa. (D) p24 release from Hep-2. (E) p24 release from
of results in CEF and BSC-40 differs from that of the other four cell lintical to that of retroviral particles from avian, simian, and
human cell lines. To determine whether the releasedpseudovirions incorporated the membrane-bound gp120
molecule, supernatants from vCP1452-infected TE671
cells labeled with [35S]cysteine/methionine were sub-
jected to centrifugation through a 20% sucrose cushion.
Analysis was then performed by immunoprecipitation
with HIV patient sera. Figure 6D shows that Gag and Env
were produced within the infected cells and that both
components sedimented efficiently through sucrose. As
expected, most of the intracellular Gag produced by
vCP1452 infection was immature (Pr55Gag), while most of
the released Gag was completely cleaved (p24, Fig. 6D).
Next, we sought to determine the amount of the pelleted
Env protein that was truly incorporated into the released
pseudovirions. For this analysis, the released particles
from metabolically labeled TE671 cells were pelleted
through sucrose, resuspended, and examined by equi-
librium density centrifugation on a linear sucrose gradi-
ent. Surprisingly, two separate peaks were seen in this
analysis (Fig. 6E). The completely cleaved Gag protein
was found at a peak density of 1.18 g/ml, consistent with
the density of retrovirus-like particles and with the gra-
dient data presented in Fig. 6C. However, there was little
Env found in these peak fractions. Instead, the Env pro-
tein was found in a peak primarily at a density of 1.15 g/ml
cted with vCP205 (open squares) or vCP1452 (filled circles) at an m.o.i.
ing infection. p24 antigen in the cellular supernatants was quantitated
06 cells. (A) p24 release from CEFs. (B) p24 release from BSC-40. (C)
5. (F) p24 release from TE671. Note that the scale used for presentationre infe
s follow
r 1 3 1(Fig. 6E, gp120/TM). This density corresponded with the
peak fraction for the uncleaved Gag protein (Fig. 6E,
278 FANG ET AL.FIG. 6. HIV-1 pseudovirion formation elicited by vCP1452. (A) Supernatants from CEFs infected with vCP1452 were harvested, filtered, purified
through a sucrose cushion, and analyzed by equilibrium sedimentation centrifugation on 20–60% linear sucrose gradients. p24 is indicated by filled
squares; the density of each fraction is indicated by open circles. (B) HIV-1 pseudovirion formation by vCP1452 infection of simian BSC-40 cells.
Processing was performed in an identical manner to that of (A). (C) Pseudovirion formation from the human muscle cell line TE671. Processing was
identical to that of (A) and (B). (D) Gag and Env protein content of cells and pseudovirion pellet. Cell lysates and supernatant were harvested from
vCP1452-infected TE671 cells following metabolic labeling with 100 mCi/ml [35S]cysteine/methionine. Lysates were directly immunoprecipitated with
HIV patient sera; supernatants were centrifuged through a 20% sucrose cushion prior to immunoprecipitation with HIV patient sera. The positions of
Pr55Gag, p24, and gp120 are indicated, and molecular mass markers in kilodaltons given at the left of the figure. C 5 cell lysate, S 5 supernatant,
M 5 marker lane. (E) Gradient analysis of released pseudovirion particles. Radiolabeled pseudovirion particles were pelleted through 20% sucrose,
resuspended, and separated on a 20–60% sucrose gradient to their equilibrium density. Fractions were immunoprecipitated using HIV patient sera.
The positions of the 1.18 g/ml p24 peak and the 1.15 g/ml Env peaks are indicated above the autoradiogram. Molecular mass markers are indicated
at the left in kilodaltons. (F) Gradient analysis of the gp120/TM molecule. Radiolabeled supernatants from cells infected with vCP124 were pelleted
through a 20% sucrose cushion and treated in an identical manner to that of (E) above.
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molecule is incorporated onto a subset of Gag
pseudovirions. Alternatively, the gp120/TM molecule may
have been incorporated into both fractions but selec-
tively lost from the denser fractions containing fully
cleaved Gag protein during processing. To test whether
the gp120 seen in this gradient was due to its presence
on pseudovirions and not on microvesicles, we repeated
this experiment using a recombinant canarypox that ex-
pressed the identical gp120 construct in the absence of
Gag (vCP124). Env produced by this vector was found to
pellet through a 20% sucrose cushion, but remained
entirely in the top (lightest) fractions of the 20–60% su-
crose gradient (Fig. 6F). We conclude that the HIV Env in
the denser fractions of the gradient shown in Fig. 6E is
present in association with Gag on pseudovirions.
Electron microscopic analysis of HIV-1 pseudovirions
produced by vCP1452
We have previously demonstrated HIV-1 pseudovirion
production by an earlier generation canarypox vector,
vCP205, from avian and mammalian cells (Fang et al.,
1999). However, production of pseudovirions by vCP205
in human cells was extremely low, and HIV-1 pseudoviri-
ons were rare upon examination of infected human cells
by electron microscopy (data not shown). To prove that
the Gag antigen detected in the experiments described
above was released as HIV pseudovirions, we performed
transmission electron microscopic analysis of vCP1452-
infected cells. HIV-1 pseudovirions were readily detected
budding from human cells (Figs. 7A, 7B, and 7D). The
diameter (110–130 nm) and appearance of particles was
identical to that of immature HIV-1 virions. The appear-
ance of HIV-1 pseudovirions produced by vCP1452 was
identical when released from the African green monkey
kidney cell line BSC-40 (Fig. 7C). Notably, all observed
pseudovirions had an immature morphology (Figs. 7C
and 7D), despite the apparent processing of the Gag
precursor (Fig. 6). We conclude that vCP1452 readily
generates HIV-1 pseudovirion formation, that released
pseudovirions are predominantly immature in morphol-
ogy, and that pseudovirion formation and release in hu-
man cells by vCP1452 is superior to that of vCP205.
DISCUSSION
The development of a successful vaccine capable of
providing protection against HIV infection or disease is
likely to be an iterative process, in which lessons learned
from early trials contribute to the development of im-
proved vaccine candidate vectors. ALVAC vCP1452 is a
second-generation canarypox HIV vaccine candidate
that is designed to enhance antigen expression in hu-
man cells. Based upon the hypothesis that PKR activa-
tion represents an important factor that has limited anti-
gen expression by earlier ALVAC-HIV vectors in humancells, two vaccinia ORFs that inhibit PKR activation were
included in the vector design. The addition of vaccinia
E3L and K3L genes to this vector thus represents a novel
attempt to increase antigen expression through the ad-
dition of modulatory genes to an attenuated poxvirus
vaccine vector. This approach was based on studies in
which E3L- and K3L-deleted vaccinia viruses were found
to be exquisitely sensitive to interferon (Beattie et al.,
1995b, 1991). The IFN-resistant phenotype of K3L-deleted
vaccinia virus was restored by reinsertion of the K3L ORF
at a distinct genetic locus or by insertion of an expres-
sion cassette for the heterologous dsRNA-binding pro-
FIG. 7. Electron micrographs of HIV-1 pseudovirions produced by
infection with vCP1452. (A and B) HIV-1 pseudovirions budding from the
surface of the human muscle cell line TE671. Magnification, 3130,520;
bar 5 100 nm. (C) HIV-1 pseudovirions released by BSC-40 cells
infected with vCP1452. Magnification, 362,750, bar 5 100 nm. (D) HIV-1
pseudovirions released by TE671 cells infected with vCP1452. Magni-
fication, 362,750, bar 5 100 nm.tein reovirus s3 (Beattie et al., 1995a,b), suggesting that
such manipulations could be applied to vectors derived
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lian cell systems. Consistent with this, in the present
study the addition of E3L and K3L resulted in significant
downmodulation of PKR activation in vCP1452-infected
cells. These results demonstrate that the inhibitory ef-
fects of E3L and K3L on PKR activation are active in a
heterologous viral context and establish the utility of this
approach in manipulating the host response directed
toward vaccine vectors. We note that the addition of
immunomodulatory genes to attenuated poxvirus vac-
cine vectors is not unique to this study. Attenuated pox-
viruses expressing human tumor antigens combined
with B7.1 and interleukin-2 (Sivanandham et al., 1998) or
with granulocyte/macrophage-colony stimulating factor
(Kass et al., 2001) as immunoadjuvants have demon-
strated promising results in mice.
It is interesting to note that the release of Gag-Env
pseudovirions by vCP1452-infected human cells per-
sisted much longer than that seen in cells infected with
vCP205. There are two likely contributing factors to ex-
plain this finding. First, the lack of PKR-mediated inhibi-
tion of translation may simply have allowed for continued
translation of viral mRNA over the 72-h period examined.
Second, the reduced cell death attributable to inhibition
of apoptosis by the actions of E3L and K3L is likely to
have contributed to ongoing expression of poxvirus-en-
coded HIV genes. Recently, Yeung and co-workers re-
ported that inhibition of PKR using an antisense strategy
led to the conversion of a normally cytolytic infection by
encephalomyocarditis virus to a persistent infection
(Yeung et al., 1999). Their study supports the idea that
viral pathogenesis may be profoundly altered through
inhibition of PKR-mediated apoptosis. Our findings with
modifications of gene expression by canarypox are in
agreement with this idea and suggest that such modifi-
cations may be a feasible approach in the creation of
more potent vaccine immunogens. The immunological
consequences of this vector modification remain to be
examined. We note also that the addition of vaccinia E3L
and K3L genes to canarypox did not relieve the host–cell
restriction on viral growth, as determined by growth
curve experiments in HeLa cells (data not shown).
The production of Gag-Env pseudovirions in human
cell lines by vCP1452 indicates that such particles may
be produced from cells of vaccinees receiving this vec-
tor. The efficient formation of Gag-Env pseudovirions by
a human muscle cell line (TE671) in particular suggests
that vaccinees receiving im injections of vCP1452 should
generate pseudovirions in vivo. Gag-Env pseudovirion
particles have been shown themselves to elicit CTL
responses in small animals and can also act as a boost
for live vector-induced cellular immunity (Arp et al., 1999).
Furthermore, macaque immunizations with pseudoviri-
ons have resulted in strong, long-lived Gag-specific
1CD8 CTL responses (Paliard et al., 2000). It is possible
that pseudovirion particles released from poxvirus-in-fected muscle cells may be taken up by professional
antigen-presenting cells and processed for presentation
by MHC class I molecules, thus enhancing the cellular
immune response beyond that which would be induced
by intracellular expression of antigen in the absence of
particle formation. This hypothesis remains to be tested
and will require a comparison of vectors encoding as-
sembly-competent and assembly-deficient Gag mole-
cules.
The pseudovirions produced by vCP1452 demon-
strated two unexplained findings. First, electron micro-
scopic analysis showed that all of the released particles
had an immature core morphology. This suggests that
processing of Gag occurred in an aberrant fashion that
prevented the formation of a mature core. Although this
may be attributable to inefficient proteolytic processing,
the majority of the Gag protein (as shown in Fig. 6D) was
completely processed. This result is consistent with our
previous examination of pseudovirion particle morphol-
ogy elicited by vCP205 (Fang et al., 1999). A second
unexplained finding was the presence of two apparent
populations of pseudovirions: one that incorporated the
truncated envelope product and peaked at 1.15 g/ml, and
one that incorporated less envelope glycoprotein and
peaked at 1.18 g/ml. Notably, some uncleaved Gag pro-
tein was associated with the lighter particle peak. While
it is possible that the immature pseudovirions seen by
electron microscopy represent only the product of the
minority, uncleaved Gag protein present in the 1.15 g/ml
peak, this seems unlikely given the abundance of parti-
cles seen and the relative paucity of the uncleaved Gag
protein. The low amount of envelope protein incorpora-
tion in the denser pseudovirion peak (1.18 g/ml) could
result from selective loss of gp120/TM from this peak
during processing or could represent a separate popu-
lation of particles that incorporate gp120/TM with lower
efficiency. Overall, the data support the ability of vCP1452
to elicit the formation of HIV pseudovirion particles and
establish that at least a subpopulation of these particles
incorporate the truncated envelope glycoprotein.
We anticipate that an increase in antigen production
by ALVAC-HIV vectors will yield enhanced immunogenic-
ity. However, it is not certain that a reduction in apoptosis
itself is a beneficial property for a vaccine construct.
There is now considerable evidence that apoptosis may
enhance antigen uptake and processing by dendritic
cells, resulting in presentation by the MHC class I path-
way (Bellone et al., 1997; Ronchetti et al., 1999). In fact, it
has been proposed that the enhanced immunogenicity of
recombinant alphavirus replicon particles depends upon
their ability to induce caspase-dependent apoptotic cell
death rather than upon the production of large amounts
of antigen (Leitner et al., 1999). Infection of immature
dendritic cells by first-generation ALVAC vectors has
recently been shown to contribute to dendritic cell mat-
uration and antigen uptake by dendritic cells in a tissue
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designing the optimal poxvirus-based HIV vaccine im-
munogen, it may be necessary to achieve a balance
between enhancing the production of antigen in infected
cells and allowing sufficient apoptosis to promote den-
dritic cell maturation and antigen uptake. It will be inter-
esting to determine in ongoing studies of the immuno-
genicity of this second-generation ALVAC vector whether
the enhanced magnitude and duration of HIV-1 antigen
production leads to an enhanced cellular immune re-
sponse. This question is currently being addressed in
comparative trials performed by the NIH-sponsored HIV
Vaccine Trials Network.
MATERIALS AND METHODS
Generation of recombinant canarypox viruses
The construction of recombinant vaccinia virus
vCP205 has been previously described (Fang et al., 1999;
Tartaglia et al., 1998b). This vector contains expression
cassettes for the HIV-1LAI gag and protease genes under
the control of the vaccinia I3L promoter, and an env
expression cassette consisting of gp120 (SU) from HIV-
1MN fused to the membrane-spanning domain of the
gp41 (TM) from HIV-1LAI. The env expression cassette is
under the control of the vaccinia virus H6 promoter.
Addition of a nef/pol polyepitope string under the control
of the H6 promoter to vCP205 resulted in the vCP1433
(Tartaglia et al., 1998a,b). vCP1452 was created by intro-
ducing vaccinia virus E3L and K3L gene expression
cassettes into vCP1433 as described below.
Insertion of vaccinia virus E3L and K3L expression
cassettes
The vaccinia virus K3L gene was synthesized by PCR,
using a plasmid containing the Copenhagen vaccinia
virus HindIII K fragment (pSD407) as template and the
oligonucleotides, MPSYN763 (59-CCCTCTAGATCGCGAT-
ATCCGTTAAGTTTGTATCGTAATGCTTGCATTTTGTTATTC-
GT-39) and MPSYN764 (59-CCCGAATTCATAAAAATTATT-
GATGTCTACA-39), as primers. This PCR fragment was
digested with XbaI and EcoRI and the resulting 315-bp
fragment, containing the K3L gene, was cloned into pBS
SK1 (Stratagene). The plasmid generated by this manip-
ulation was designated pBS763/764. The K3L gene was
then cloned downstream from the vaccinia virus early/
late H6 promoter (Perkus et al., 1989). This was accom-
plished by cloning the 340-bp NruI–XhoI fragment from
pBS763/764, containing the K3L gene, into a plasmid con-
taining the H6 promoter (pMM154). The plasmid gener-
ated by this manipulation was designated pMPTKH6K3L.
A selectable marker was then cloned into pMPTKH6K3L.
This was accomplished by cloning a 700-bp SmaI–
BamHI fragment from pMP42GPT, containing an Esche-
richia coli gpt expression cassette, into pMPTKH6K3L.The plasmid generated by this manipulation was desig-
nated pMPTKH6K3Lgpt. The K3L and gpt expression
cassettes were then cloned into an ALVAC insertion
plasmid. This was accomplished by cloning the 1.2-kb
XhoI fragment from pMPTKH6K3Lgpt, containing the K3L
and E. coli gpt expression cassettes, into the ALVAC
insertion plasmid, pC6L. The plasmid generated by
this manipulation was designated pMPC6H6K3Lgpt.
The vaccinia virus E3L gene was then cloned into
pMPC6H6K3Lgpt. This was accomplished by cloning the
2.3-kb EcoRI fragment from pSD401VC, containing the
Copenhagen vaccinia virus E3L gene (and the E3L early
promoter), into pMPC6H6K3Lgpt. The plasmid generated
by this manipulation was called pMPC6H6K3E3gpt. The
K3L and E. coli gpt expression cassettes were then
removed by digesting pMPC6H6K3E3gpt with XhoI and
self-ligating the resulting 6.8-kb fragment. The plasmid
generated by this manipulation was called pMPC6E3.
The K3L expression cassette was then cloned into
pMPC6E3. This was accomplished by cloning the 560-bp
PspAI fragment from pMPTKH6K3L, containing the H6-
promoted K3L expression cassette, into pMPC6E3. The
plasmid generated by this manipulation, pMPC6H6K3E3,
was transfected into CEFs that were simultaneously in-
fected with vCP1433 to generate viruses incorporating
E3L and K3L genes at the C6 locus by homologous
recombination. Recombinant viruses were identified by
Southern blotting using probes specific for E3L and K3L
and were purified by multiple rounds of plaque purifica-
tion. The resulting recombinant virus was designated
vCP1452. The nucleotide sequence of the regions of the
canarypox genome used for the generation of transfer
plasmids is available upon request.
One experiment depicted in Fig. 3 was performed with
recombinant canarypox vCP124. This virus contains the
same gp120/TM cassette as that of vCP205 and
vCP1452, but lacks the gag/pro expression cassette. In
this construct the gp120/TM cassette was cloned into the
C5 locus using the same procedures as described
above.
Detection of E3L, K3L expression in human cells
Chicken embryo fibroblasts (CEFs) were mock in-
fected or infected with parental ALVAC (containing no
heterologous genes) or vCP1452 at an m.o.i. of 10 PFU/
cell in methionine- and cysteine-free media supple-
mented with 100 mCi/ml [35S]cysteine/methionine. The
cells were lysed 18 h postinfection, and the lysates
immunoprecipitated with rabbit antisera against E3L
(Watson et al., 1991) or rabbit antisera against K3L
(Beattie et al., 1995b).
Preparation of virus stocksPrimary chicken embryo fibroblasts were prepared
from 8- to 10-day-old chicken embryos and were main-
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HI-Chick serum, 10% tryptose-phosphate broth, 0.056%
sodium bicarbonate, 100 U/ml penicillin, and 100 mg/ml
streptomycin. Viral stocks were prepared in primary
chicken embryo fibroblasts as previously described
(Fang et al., 1999). CEFs were infected at an m.o.i. of 0.1
using a vaccine seed stock prepared at Virogenetics
Corp. (Troy, NY). Infected flasks were incubated at 37°C
for 3–5 days until maximum cytopathic effect was appar-
ent. Working stocks were generated by freeze-thawing,
sonicating, and clarification of the sonicate by centrifu-
gation at 1000 g for 10 min at 4°C. Plaque titering of
canarypox stocks was performed as described (Fang et
al., 1999). Resulting virus stocks were stored at 270°C
until needed.
Analysis of PKR phosphorylation
Tissue culture dishes (100 mm2) were seeded with
HeLa cells in sufficient number to achieve 40% conflu-
ence on the night prior to treatment. The cells were
incubated with or without b-interferon (50 units/ml, Cal-
biochem) for 18 h prior to viral infection. The cells were
then infected with vCP1452 or vCP205 at an m.o.i. of 10
in 2 ml of complete nutrient media. Control plates were
mock infected with an equivalent volume of phosphate-
buffered saline (PBS). Four hours postinfection, the cells
were washed with phosphate-free DMEM with 0.1% FCS
and incubated in the same phosphate-free medium con-
taining 200 mCi/ml [32P]orthophosphate (Amersham) for
1 h. The cells were then harvested in 0.5 ml NP-40 lysis
buffer (150 mM NaCl, 50 mM Tris–HCl pH 8.0, and 1%
NP-40) and lysed by three cycles of freeze-thawing, and
the lysates clarified by centrifugation at 13,000 g for 15
min at 4 °C. 32P-labeled PKR was immunoprecipitated
using rabbit polyclonal anti-PKR antiserum (Santa Cruz
Biotechnology) and analyzed via SDS–PAGE and autora-
diography. Western blotting was carried out by transfer-
ring an aliquot of each immunoprecipitated sample to
nitrocellulose and immunoblotting with a murine mono-
clonal antibody directed against PKR (Santa Cruz Bio-
technology). Quantitation of 32P-labeled PKR was per-
formed by scanning of autoradiographs on a flatbed
scanner, followed by quantitation of the p68 bands using
the program NIH Image (version 1.61).
Measurement of virus-mediated apoptosis
DNA fragmentation was assessed in HeLa cells fol-
lowing infection with vCP205 or vCP1452. Monolayers of
HeLa cells grown in 100-mm2 plates (4 3 107 cells/plate)
were infected at an m.o.i. of 10 with vCP205 or vCP1452.
Cells were scraped and collected in media at 8 and 12 h
postinfection, washed once with PBS, and lysed in bind-
ing/lysis buffer (6 M guanidine–HCl, 10 mM urea, 10 mM
Tris–HCl, 20% Triton X-100, pH 4.4). After adding isopro-
panol to 20% (v/v) and shaking, the lysate was applied topolypropylene tubes containing glass fiber fleece. Cellu-
lar DNA was captured on the glass fibers, washed, and
eluted with 10 mM Tris–HCl, pH 8.5. Samples were an-
alyzed on a 1.5% agarose gel containing 0.1 mg/ml of
ethidium bromide. A second assay for apoptosis em-
ployed a commercial kit for measurement of cytoplasmic
histone-associated DNA fragments (Cell Death Detec-
tion ELISA, Roche Molecular Biochemicals). Detection of
mono- and oligonucleosomes was performed according
to the manufacturer’s instructions using cytoplasmic ex-
tracts from HeLa cells harvested 24 h postinfection with
vCP205 or vCP1452. Experiments were performed in trip-
licate.
p24 antigen release in human cell lines
p24 antigen production and release was measured
using a p24 capture ELISA (Organon-Teknika, Raleigh,
NC). BSC-40 cells were obtained through Bernard Moss
(NIH, Bethesda, MD). The following cell lines were ob-
tained through the American Type Culture Collection
(ATCC): HeLa, derived from a human cervical carcinoma
(ATCC CCL-2); Hep-2, derived from a human epidermoid
carcinoma (ATCC CCL-23); TE671, a human rhabdomyo-
sarcoma cell line (ATCC CRL-8805); and MRC-5, a human
lung fibroblast cell line (ATCC CCL-171). Cells were
plated in the evening in 100 mm2 dishes at a density that
achieved 70% confluence by the next morning. Precise
cell numbers were obtained by counting the cells at this
time to normalize the viral m.o.i.; the total number of cells
varied by the particular cell type. Cells were infected at
an m.o.i. of 10 with vCP205 or vCP1452. Supernatants
were harvested at multiple time points up to 72 h postin-
fection and assayed for p24 content. The number of cells
present at the time of infection was used to normalize the
p24 release data to facilitate comparisons of the effi-
ciency of release from individual cell lines (reported as
nanograms of p24 released per 1 3 106 cells).
Analysis of HIV pseudovirion formation by equilibrium
density centrifugation
Pseudovirion formation and release from cells was
analyzed by equilibrium density centrifugation on linear
sucrose gradients. Cells were infected with vCP1452 at
an m.o.i. of 10. Seventy-two hours postinfection, cellular
supernatants were harvested, filtered through a 0.45-mm
filter, layered over a 20% sucrose gradient, and subjected
to centrifugation at 100,000 g for 3 h. Particulate matter
that sedimented through the sucrose cushion was resus-
pended in PBS and layered on the top of a 20–60% linear
sucrose gradient. Equilibrium density centrifugation was
carried out by centrifugation at 100,000 g for 16 h in an
SW41ti rotor (Beckman). One milliliter fractions were col-
lected from the bottom of the gradient. p24 antigen con-
tent in each fraction was quantified using p24 antigen-
capture ELISA. For the detection of Gag and Env anti-
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vCP205 or vCP1452, and complete DMEM replaced with
media deficient in methionine and cysteine supple-
mented with 100 mCi/ml [35S]cysteine/methionine. Cells
and supernatants were collected 16 h later; cells were
lysed in RIPA buffer (1% NP-40, 0.1% SDS in PBS) and
subjected to immunoprecipitation with pooled HIV pa-
tient sera. Supernatants were subjected to pelleting and
centrifugation on 20–60% sucrose gradients as de-
scribed above; gradient fractions were then immunopre-
cipitated with pooled HIV patient sera. Analysis was
performed via SDS–PAGE and fluorography.
Detection of Gag-Env pseudovirions by electron
microscopy
Cells were harvested 24 h following infection with
vCP205 or vCP1452, washed in PBS, and fixed in 2%
glutaraldehyde in PBS. Dehydration, embedding, and
sectioning were performed as described previously
(Fang et al., 1999). Sections were examined and photo-
graphed using a Phillips Model 3000 electron micro-
scope.
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